article thumbnail

Deadline 2030: The Shape of Things to Come

Velocity of Content

How will the landscape look in 2030 and will it be significantly different? The post Deadline 2030: The Shape of Things to Come appeared first on Copyright Clearance Center. Will some of today’s challenges have been resolved by then? Will new ones emerge? The other events will take place 10 November and 2 December. .

article thumbnail

The Road Ahead – ???????????? 2030

JD Supra Law

Singapore Intellectual Property Strategy 2030????SIPS SIPS 2030??????????. World Intellectual Property Day???????????????IP IP Office of Singapore????IPOS???Singapore’s Singapore’s 2013 IP Hub Master Plan (and 2017 updates)?????Singapore By: Dentons

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Road Ahead - Singapore’s Intellectual Property Strategy 2030

JD Supra Law

On this year’s World Intellectual Property Day, the IP Office of Singapore (IPOS) announced the Singapore Intellectual Property Strategy 2030 (SIPS 2030), built on Singapore’s 2013 IP Hub Master Plan (and 2017 updates).

article thumbnail

Video entertainment in 2030

McKinsey Operations

McKinsey experts predict that video entertainment, in all its forms, will become more immersive, gamified, and personalized.

130
130
article thumbnail

Battery 2030: Resilient, sustainable, and circular

McKinsey Operations

Battery demand is growing—and so is the need for better solutions along the value chain.

134
134
article thumbnail

Claims 2030: Embracing the future

McKinsey Operations

As technological change accelerates and customer preferences diverge, the future of claims organizations centers on four key trends.

article thumbnail

Sandoz Announces New Global ‘Act4Biosimilars’ Initiative, to Improve Patient Access and Increase Adoption by At Least 30% in 30+ Countries by 2030

LexBlog IP

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.